Piper Sandler cuts Humana stock price target on updated estimates

Piper Sandler cut its Humana price target to $182 from $265 while keeping a Neutral rating; shares trade around $173.62, roughly 32% YTD down and near a 52-week low of $169.61. Piper Sandler models assume modest Medicare Advantage rate growth and projects $24.25 of consolidated adjusted EPS for 2028, with quality-bonus benefits potentially worth up to ~120bps (Individual) and ~370bps (Group) under a 75% 4-star scenario. Humana completed a $1.0B 2056 junior subordinated note issue at 6.625% (net proceeds ≈ $986M) and declared a $0.885 quarterly dividend payable April 24, 2026; UBS reiterated Neutral ($195 PT) while Barclays cut its PT to $176.

Analysis

Humana’s current stress is not just an earnings miss — it amplifies structural scale advantages across Medicare Advantage. Insurers with broader membership bases and vertically integrated care assets can absorb MA rate volatility and preserve margins by reallocating care management spend; that creates a durable competitive wedge that will pressure medium-sized carriers’ retention and pricing power over 6–18 months.

A crystallizing risk is binary: regulatory/quality-bonus outcomes and risk‑adjustment reversals. These can swing effective spreads and MLRs materially from one benefit year to the next, so headlines around CMS audits, retroactive risk‑adjustment adjustments, or a big uptick in quality scores would compress implied downside (days–weeks), while sustained enrollment/margin pressure is a multi-quarter to multi-year readjustment.

Second‑order supply‑chain effects: providers and care-management vendors increasingly face payment re‑negotiation risk; expect accelerated contract consolidation among vendors servicing multiple MA plans, which benefits large national vendors and pressures smaller specialty providers’ cash flow in 6–12 months. Capital markets response will be phased: equity derisking first, then credit repricing if margin erosion persists — creating tactical windows in both equity and credit markets.

Consensus may be overweighing near-term margin risk and underweighting upside optionality from improved star‑rating capture or targeted benefit redesigns. A modest recovery in claims mix or a one-year improvement in risk‑adjustment realization could re-rate the stock asymmetrically because forward multiples already embed conservative growth; that makes small, optionality‑oriented longs attractive versus blunt, size‑heavy shorts.

Key Decisions for Investors

• Short HUM equity via a 6–9 month put spread (buy puts, sell lower strike puts) sizing at 1–2% NAV to limit carry. Rationale: asymmetric downside protection if MA margins disappoint; target payoff 3:1 if HUM declines ~20–30%. Close if CMS risk‑adjustment releases or star‑rating signals beat consensus.
• Pair trade: long UNH (or CVS) stock vs short HUM stock, 1:1 notional, 9–12 month horizon. Rationale: capture scale advantage and investor re‑rating toward larger, vertically integrated MA players; target 30–40% relative outperformance. Hedge with collars if concerned about macro equity drawdowns.
• Convex contrarian: small allocation (0.5–1% NAV) to long-dated HUM call LEAPs (12–18 months) as a binary upside play if quality bonus capture or risk‑adjustment reversals surprise positively. Risk limited to premium; reward asymmetric if market reprices forward margins.